Alembic Pharmaceuticals , a leading Indian pharmaceutical company, has announced strong financial results for the first quarter, demonstrating resilience and growth across its business segments.

Financial Highlights

• Revenue from operations increased by 10% year-over-year to ₹1,710.72 crore
• EBITDA grew by 20% to ₹288.00 crore, with EBITDA margin expanding to 17% of revenue
• Net profit rose by 15% to ₹154.38 crore
• Earnings per share (EPS) improved to ₹7.85, up from ₹6.84 in the previous year's corresponding quarter

Segment Performance

Alembic Pharma's growth was driven by strong performances across its key business segments:

India Branded Business

• Delivered a 5% year-on-year growth, reaching ₹599.00 crore in revenue
• Showed good momentum in specialty therapies, particularly in Gynaecology, Cardiology, Anti-Diabetic, Ophthalmology, and Animal Healthcare

US Generics

• Grew by 13% to ₹523.00 crore, despite ongoing pricing pressures
• Successfully launched 4 new products in the US market during the quarter

Ex-US International Generics

• Reported an impressive 21% growth to ₹328.00 crore
• Reflects the company's strategic expansion in international markets

API Business

• Remained stable with a 1% growth to ₹261.00 crore
• Balanced volume growth against pricing pressures

Operational Highlights

• R&D expenses stood at 8% of revenue
• Received 6 ANDA approvals during the quarter
• Cumulative ANDA approvals reached 223
• Successfully introduced 3 new products in the Indian market

Management Commentary

Mr. Pranav Amin, Managing Director of Alembic Pharmaceuticals Limited, commented on the results: "We began the quarter on a strong note, delivering revenue growth across all businesses. The growth was driven by a 21% increase in RoW markets, reflecting our strategic expansion and disciplined execution across geographies. Despite ongoing pricing pressure, our US business grew by 13%, supported by volume gains. As we ramp up utilization of our new manufacturing facilities and continue to drive cost optimization initiatives, we expect to benefit from improved operating leverage."

Future Outlook

Alembic Pharmaceuticals is well-positioned for continued growth, with a robust pipeline of over 15 product launches expected. The company's focus on expanding its presence in international markets, coupled with its strong R&D capabilities, is likely to drive future performance.

The company's strategic initiatives, including the ramp-up of new manufacturing facilities and ongoing cost optimization efforts, are expected to enhance operational efficiency and profitability in the coming quarters.

Conclusion

Alembic Pharmaceuticals' quarterly results demonstrate the company's ability to navigate challenging market conditions while delivering solid growth across its diverse business segments. With a strong product pipeline, expanding global presence, and focus on operational excellence, Alembic Pharma appears well-equipped to capitalize on growth opportunities in the pharmaceutical sector.

Alembic Pharmaceuticals , a prominent player in the Indian pharmaceutical industry, has announced a significant change in its senior management. Mr. Shreekumar Nair, who held the position of President-Supply Chain Management and Operations, has retired from his role at the company.

Retirement Details

According to the official communication from Alembic Pharmaceuticals to the stock exchanges:

• Effective Date: Mr. Nair's cessation from his role took effect on July 31, 2025, after the closure of business hours.
• Reason for Change: The company cited superannuation as the reason for Mr. Nair's departure.

Company Disclosure

Alembic Pharmaceuticals made this announcement in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided the following details in its regulatory filing:

• The change in senior management personnel was officially communicated to both the BSE Limited and the National Stock Exchange of India Ltd.
• The company's filing included an annexure with specific details as required by SEBI regulations.

Impact and Future Steps

While the company has not provided information about a successor or the immediate plans for the Supply Chain Management and Operations department, such changes in senior management can be significant for a company's operations.

Alembic Pharmaceuticals, known for its presence in various pharmaceutical segments, will likely ensure a smooth transition in its supply chain and operations following Mr. Nair's retirement. The company's ability to manage this change effectively could be crucial for maintaining its operational efficiency and market position in the competitive pharmaceutical industry.